For U.S. users: The VLVbio K18 assays have not been approved by the U.S. Food and Drug Administration
M65® ELISA
Product no. 10020
The assay, based on the M5 and the M6 antibodies, measures total cell death due to apoptosis or necrosis and is intended for human serum or plasma. The assay is CE marked as a medical device for in vitro diagnostic use.
General Information
M65® ELISA M65® ELISA M65® ELISA M65® ELISA M65® ELISA
Product characteristics
The M65® ELISA measures total cell death due to apoptosis or necrosis by quantifying the levels of total soluble keratin 18 (K18) released from dying epithelial cells.
Assay type: Sandwich ELISA, 96-wells, ready-to-use. Pre-coated microplate (12 x 8 well strips)
Sample type: Human serum and plasma, Human cell cultures and spheroids (epithelial K18 positive cells), Xenograft models
Assay time: 2 hours
Storage instructions: Store at 2-8 °C
Species reactivity: Reacts with Human
Assay Procedure
Assay Procedure of M65® ELISA
Application Fields
Hepatology
The M65® ELISA can be used to measure the levels of total hepatocyte cell death in patients with certain liver diseases, e.g. Non-alcoholic Steatohepatitis, Alcoholic Steatohepatitis and Acute-On-Chronic Liver Failure.
Oncology
In the field of oncology, the M65® ELISA can be used to investigate and identify compounds and anticancer drugs inducing cell death in epithelial carcinomas.
Toxicology
The M65® ELISA can be used to detect elevated levels of K18 as a result of hepatotoxicity caused by exposure of pharmaceutical agents’ or toxic substances, the case in e.g. Drug-Induced Liver Injury or Toxicant-Associated Steatohepatitis.
M65® ELISA in:
CLINICAL APPLICATION
Non-Alcoholic Steatohepatitis
NASH is a progressive and serious form of Non-alcoholic Fatty Liver Disease (NAFLD), and has during the last couple of decades become one of the most common causes of liver disease globally and a public health problem.
The number of affected patients is growing rapidly and the disease affects a considerable share of today’s global population.
CLINICAL APPLICATION
Alcoholic Steatohepatitis
Excessive alcohol use is a large global problem where around 300 million people around the world have an alcohol use disorder. This can lead to alcohol associated liver disease (ALD), a chronic liver disease that can further lead to Alcoholic Steatohepatitis (ASH), liver fibrosis and eventually cirrhosis.
Routine liver function tests used today often fail to detect and monitor liver damage due to ALD.
Together with other products
When the M65® ELISA is used together with the M30 Apoptosense® ELISA, the cell death mode can be further analysed As both assays are calibrated against the identical reference, the combination of the M30 Apoptosense® ELISA and the M65® ELISA allows determination of the relative contribution of apoptosis to total cell death.
